ABSTRACT
SARS-CoV-2 variants have emerged in late 2020 and there are at least three variants of concern (B.1.1.7, B.1.351, P1) reported by WHO. These variants have several substitutions in the Spike protein that affect receptor binding; they present increased transmissibility and may be associated with reduced vaccine effectiveness. In the present work, we are reporting the identification of a potential variant of interest harboring the mutations T478K, P681H, and T732A in the Spike protein, within the newly named lineage B.1.1.519, which rapidly outcompeted the preexisting variants in Mexico and has been the dominant virus in the country during the first trimester of 2021.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was partially supported by grants Epidemiologia Genomica de los Virus SARS-CoV-2 Circulantes en Mexico and Caracterizacion de la diversidad viral y bacteriana" from the National Council for Science and Technology (CONACyT) of Mexico to C.F.A. and J.A.V.P. respectively and also grants 057, 047 and 072 from the Ministry of Education, Science, Technology and Innovation (SECTEI) of Mexico City to C.F.A., L.H.M. y A.H.M. respectively
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Residual RNA positive samples were recovered and sequenced from routine SARS CoV-2 diagnostic and were processed following Standardized Guideline for Epidemiological and Laboratory surveillance of Viral Respiratory Disease (https://www.gob.mx/cms/uploads/attachment/file/610162/Lineamiento_VE_y_Lab_Enf_Viral_Ene-2021_290121.pdf) emitted and approved by the CONAVE (National Counsel of Epidemiology Surveillance) of the Secretariat of Health, Government of Mexico. This work was also approved for the Ethics Committee on Research of the National Institute of Genomic Medicne with the registration number of the National Bioethics Commission CONBIOETICA-09-CEI-008-20180615 under the opinion number CEI 2020/20. All data obtained in this work are directly related to disease control and were openly available at the GISAID website to the public before the initiation of the study.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
